Curated CRC research — accessible, accurate, actionable

The CRC Digest

Thursday, July 30, 2026

Was this forwarded to you? Read on the web or subscribe free

IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.

CRC Research Update

• ◆ TRIAL DATA

  Phase III trial tests chemotherapy plus immunotherapy in MSI-H metastatic colorectal cancer

  The phase III COMMIT trial randomly assigned first-line mismatch repair-deficient metastatic colorectal cancer patients in a three-arm study comparing mFOLFOX6/bevacizumab/atezolizumab versus atezolizumab monotherapy, testing whether adding chemotherapy to immunotherapy improves outcomes. (Journal of Clinical Oncology)

• ▪ SCREENING

  Blood-based surveillance after surgery increased curative treatment for recurrence

  The phase III FIND trial showed that ctDNA methylation-guided surveillance in nonmetastatic colorectal cancer patients after surgery led to higher rates of curative-intent therapy for recurrence compared to standard CT-based monitoring. (Journal of Clinical Oncology)

• ▪ SCREENING

  Multi-cancer blood tests may not match colonoscopy for colorectal cancer prevention

  A modeling study found that multi-cancer early detection blood tests offer little opportunity for cancer prevention through precursor lesion removal, raising questions about whether detecting multiple cancers can offset the loss of colorectal cancer prevention provided by colonoscopy and FIT. (medRxiv, preprint)

• ▸ TREATMENT

  Liquid biopsy may guide HER2-targeted therapy rechallenge in metastatic disease

  Real-world data suggest that monitoring HER2 amplification through liquid biopsy can help identify patients with HER2-amplified metastatic colorectal cancer who may benefit from rechallenge with anti-HER2 therapy. (JCO Precision Oncology)

These findings highlight progress in personalized surveillance and treatment strategies for colorectal cancer patients.

Editorial note: one or more studies referenced above are preprints and have not yet been peer-reviewed; findings are preliminary and may change before formal publication.